Physician profile
Steven J Waltrip
NPI 1467423046
$10,983.45
in general payments reported to CMS, 2019-2025
36 companies · $385 in 2025
The $385 reported for 2025 was more than what 83% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,603 · 2020: $1,487 · 2021: $1,745 · 2022: $2,686 · 2023: $1,220 · 2024: $858 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,622.38 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Bioventus LLC | $1,410.71 | 2019-2025 | Gelsyn-3, Xcell, L360 Thigh System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,177.53 | 2019-2025 | Relistor |
| Pacira Pharmaceuticals Incorporated | $1,070.97 | 2022 | |
| Collegium Pharmaceutical, INC. | $989.31 | 2019-2023 | Belbuca |
| Fidia Pharma USA INC. | $849.57 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Daiichi Sankyo INC. | $701.36 | 2019 | |
| Pacira Therapeutics, INC. | $457.41 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $313.55 | 2019-2022 | |
| Novo Nordisk INC | $272.47 | 2019-2022 | |
| Janssen Biotech, INC. | $250.52 | 2019-2020 | |
| Horizon Therapeutics Plc | $207.36 | 2020-2022 | |
| Redhill Biopharma INC. | $203.27 | 2020-2022 | |
| Depuy Synthes Sales INC. | $200.38 | 2021-2025 | Orthovisc |
| Boston Scientific Corporation | $138.79 | 2019-2025 | General - Pain Management |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $132.64 | 2019-2021 | |
| Amgen INC. | $117.35 | 2020-2023 | Prolia, Evenity |
| Abbvie INC. | $102.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $91.02 | 2019-2020 | |
| Zyla Life Sciences, INC. | $89.45 | 2019-2020 | |
| Abbott Laboratories | $73.33 | 2019-2024 | Proclaim, Eterna |
| Virtus Pharmaceuticals LLC | $68.01 | 2023-2024 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $55.95 | 2023 | Movantik |
| Nevro Corp. | $54.44 | 2024 | Senza |
| Uswm, LLC | $53.87 | 2022 | |
| Zimmer Biomet Holdings, INC. | $45.16 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Glaxosmithkline, LLC. | $34.10 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $31.91 | 2022 | |
| Merz Pharmaceuticals, LLC | $26.60 | 2023 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $25.90 | 2023 | Seglentis |
| Pfizer INC. | $21.59 | 2020 | |
| Alfasigma USA, INC. | $20.17 | 2021 | |
| Sentynl Therapeutics, INC. | $19.95 | 2019 | |
| Forte Bio-Pharma LLC | $19.92 | 2020 | |
| Merck Sharp & Dohme LLC | $18.50 | 2019 | |
| Antares Pharma, INC. | $15.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Waltrip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.